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Abstract
Background: To validate an artificial neural network (ANN) based on the combination of PSA
velocity (PSAV) with a %free PSA-based ANN to enhance the discrimination between prostate
cancer (PCa) and benign prostate hyperplasia (BPH).
Methods: The study comprised 199 patients with PCa (n = 49) or BPH (n = 150) with at least
three PSA estimations and a minimum of three months intervals between the measurements.
Patients were classified into three categories according to PSAV and ANN velocity (ANNV)
calculated with the %free based ANN "ProstataClass". Group 1 includes the increasing PSA and
ANN values, Group 2 the stable values, and Group 3 the decreasing values.
Results: 71% of PCa patients typically have an increasing PSAV. In comparison, the ANNV only
shows this in 45% of all PCa patients. However, BPH patients benefit from ANNV since the stable
values are significantly more (83% vs. 65%) and increasing values are less frequently (11% vs. 21%)
if the ANNV is used instead of the PSAV.
Conclusion: PSAV has only limited usefulness for the detection of PCa with only 71% increasing
PSA values, while 29% of all PCa do not have the typical PSAV. The ANNV cannot improve the PCa
detection rate but may save 11–17% of unnecessary prostate biopsies in known BPH patients.
Background
Prostate specific antigen (PSA) is accepted as screening
test for prostate cancer (PCa) detection but has its limita-
tions especially in test specificity [1]. To improve PSA spe-
cificity, many methods have been introduced, e.g.
measurements of molecular forms of PSA like free PSA
[2,3], PSA in relation to prostate volume (PSA density,
PSAD) [4], age related reference PSA values [5] or PSA
changes over time which is known as PSA velocity (PSAV)
[6]. To date only the use of percent free PSA (%fPSA) has
been clinically accepted to improve specificity [7].
Recently the clinical usefulness of PSAV has debated
intensively. Some authors argue for a lower cutoff for
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PSAV of 0.4 ng/mL per year instead of the former 0.75 ng/
mL per year cutoff especially in younger men [8]. Others
introduced age adjusted PSAV and PSA cutoffs for biopsy
indication [9]. For younger patients (age 50–59) the PSAV
cutoff should be lowered to 0.4 ng/mL per year to
improve specificity [9]. Ito et al. [10] described a yearly
threshold of 0.3 ng/mL as the optimal cutoff value of
PSAV if the initial PSA level is 1–1.9 ng/mL and 0.75 ng/
mL if the initial PSA is 2–4 ng/mL. Berger et al. [11] found
significant differences in PSAV between PCa and patients
with no evidence of malignancy.
In contrast, two recent studies did not prove the addi-
tional value of PSAV over PSA alone [12,13]. When con-
sidering the large biological variability of PSA of up to
20% [14] or differences in PSA values regarding the used
assay [15] this may lead to misinterpretation. Different
values are even more obvious when considering %fPSA
[16-18].
An improved PCa detection rate was shown when using
multivariate models like logistic regression [19] or artifi-
cial neural networks [20] which include %fPSA, PSA, and
partially patient age, prostate volume and other clinical
factors as input variables. However, until now the param-
eter PSAV has not been included in such a multivariate
model.
The aim of this study was to combine both methods, the
ANN and PSAV, and to validate the diagnostic usefulness
of this new model with regard to the differentiation
between PCa and benign prostate hyperplasia (BPH). For
that purpose, we compared the diagnostic usefulness of
the conventional PSAV and other parameters with the so-
called ANN velocity (ANNV) that included the PSA and
free PSA velocity data into an ANN model.
Methods
From a cohort of 2959 patients visiting the Department of
Urology (Charité Hospital Berlin) with total PSA (tPSA)
and free PSA (fPSA) measurements from 1996–2006, a
total of 199 patients were included. The selection criteria
for this PSAV and ANNV study were at least three PSA and
fPSA measurements with a minimum of three months
interval between two measurements before treatment. All
serum samples were drawn before any prostate manipula-
tion (or at least 3–4 weeks after an earlier manipulation)
and centrifuged within 2–3 hours after sampling. The
samples were analyzed immediately or stored at -20°C for
no longer than 48 hours before assay. The study was car-
ried out in accordance with the standards of the local eth-
ics board and the Helsinki Declaration of 1975 as revised
in 1996.
All 199 patients (44–85 years) had a histological proven
diagnosis of PCa (n = 49) or BPH (n = 150) based on
examination of tissue samples obtained by transrectal
ultrasound (TRUS)-guided sextant (until 1999) or octant
prostate biopsies. Additionally, the status of digital rectal
examination (DRE), age, and prostate volume (measured
by TRUS) were also available.
Total and free PSA were measured with the IMMULITE
PSA and Free PSA kits (Diagnostic Products, Los Angeles,
CA, USA). The analytical performance and comparisons
to other PSA tests have been described earlier [18,21].
Prostate volume was determined by TRUS using the pro-
late ellipse formula. A DRE finding non-suspicious for
cancer was defined as negative and a finding suspicious
for cancer as positive. All patients had a complete data set
on tPSA, %fPSA, age, prostate volume, and DRE status at
the time of the last PSA and fPSA measurement. In 14 of
the 150 BPH patients (9.3%) the ANNV was not calcu-
lated using the first but the first available complete data
set (fPSA and tPSA at 2nd or 3rd measurement) since par-
tially the fPSA was not measured when tPSA was less than
2 ng/mL (1996–1999) or less than 1 ng/mL (1999–2006).
PSA values were included in the velocity calculation using
the formula: (last PSA – first PSA)/time interval in ng/mL/
year). Based on this formula, a one year short-term-PSAV,
which describes the PSAV within the last 12 months
before diagnosis, was also calculated.
The ANNV was calculated analogous with the ANN out-
put values instead of the PSA values by using the same for-
mula (last ANN output – first ANN output/time interval).
The ANN was constructed with the SPSS-module Neural
connection 2.0 (SPSS) as described earlier [22]. The back-
propagation network consists of one input layer with the
five neurons tPSA, %fPSA, patient age, prostate volume,
and DRE status. Each ANN contains one hidden layer with
three neurons. Each ANN finally contains one output neu-
ron representing the output value as the probability of
PCa. The activation function for the hidden neurons was
the tanh while the activation function for the output neu-
ron was linear in the range 0 to 1 to get a value for the
probability of PCa. Training of the ANN took place in 4
steps with 100 sweeps each of them. Stopping criteria
were a RMS error less than 0.001 or a rate of 95% correct
classified samples. The initial weights were set randomly
to values between -1 and +1. Before training all variables
were normalized to mean value 0 and standard deviation
1 and ordered randomly. To avoid over-fitting we used 10-
fold cross-validation. During training always 10% of the
data were used for internal validation.
The respective PSA- and ANN-follow ups were divided
into three groups. Group 1 consisted of increasing valuesBMC Urology 2008, 8:10 http://www.biomedcentral.com/1471-2490/8/10
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(PSA >0.75 ng/mL/year; ANN >4/year), group 2 of stable
values (PSA -0.75 to 0.75 ng/mL/year; ANN -4 to 4/year),
and group 3 of the decreasing follow up values (PSA <-
0.75 ng/mL/year; ANN <-4/year). When analyzing the fol-
low up of %fPSA only, it has been shown that due to the
large variability between the measurements there is no
usefulness at all for the parameter %fPSA velocity (data
not shown).
Statistical calculations were performed with SPSS 14.0 for
Windows (SPSS, Chicago, USA). We used the non-para-
metric Mann-Whitney U test and the Kruskal-Wallis test.
The diagnostic validity of all parameters was evaluated by
Receiver-operating characteristic (ROC) curve analysis.
The areas under the ROC curves (AUCs) and the specifici-
ties at 90% and 95% sensitivity were compared by a non-
parametric method using the software GraphROC 2.1 for
Windows. Significance was defined as P < 0.05.
Results
The median tPSA for the PCa patients at the time of diag-
nosis (last tPSA value) was 8.3 ng/mL (range 3.2–107 ng/
mL). The BPH patients had a significantly lower (P  <
0.0001) median tPSA value of 5.3 ng/mL (0.4–37.1 ng/
mL). Descriptive data for all analyzed tPSA ranges 0–4,
4.1–10, 10.1–20 and >20 ng/mL for all PCa and BPH
including the median tPSA, %fPSA and prostate volume
are shown in Table 1. The median age for all patients was
68 years and the age distribution revealed no differences
between the 4 tPSA groups for the PCa where the median
age was 66 years (45–80 years). The median age for the
BPH patients was somewhat but not significantly higher
(68 years, range: 44–85, P = 0.1) but did also not differ
between the 4 groups.
Regarding the follow up of the PCa patients, the number
of PSA and fPSA measurements ranged from 3 to 13
(median: 4.5) whereas the BPH patients had on average
more PSA and fPSA measurements (range 3 to 22,
median: 7). The distribution of the follow up related to
the years before diagnosis of PCa or total follow up time
for the BPH patients is shown in Table 2. The median fol-
low up time for all patients was 3.4 years while PCa
patients had a shorter median follow up (1.8 years) com-
pared with BPH patients (4.2 years).
Table 3 shows the ROC analysis for all 199 patients by
comparing the AUC for tPSA, %fPSA, PSAD, PSAV, ANN
output and the ANNV. PSAD was the best parameter to
differentiate between PCa and BPH and neither ANN nor
ANNV could improve this. At 95% sensitivity, PSAD per-
formed better than all other parameters. On the other
hand, at 95% specificity, the ANNV was the best available
parameter with a sensitivity of 32.7% and significantly
better performance compared with all others except
%fPSA (P = 0.44). A similar behavior is seen for the 4–10
ng/mL tPSA range in Table 4. Again, regarding the AUC
comparison and the specificities at 95% sensitivity, PSAD
performed best, but did only reach significance levels to
all others at 95% sensitivity but not for the AUC compar-
ison. At 95% specificity, the ANNV (sensitivity 37.5%)
demonstrated also within the tPSA range 4–10 ng/mL the
ability to perform significantly better than all other
parameters except the ANN output (P = 0.07). Figure 1
shows for the tPSA range 4–10 ng/mL that the ANNV has
the steepest increase of the ROC curve with the highest
sensitivities at 95% and 90% specificity, respectively. This
may be more important for repeat biopsies, where biop-
sies in general should be avoided.
In Table 5 the respective three groups for PSAV and ANNV
(increasing, stable and decreasing values) are given. More
than two third of all PCa patients have the typical increas-
ing PSAV. In comparison, the ANNV is only indicated at
45% of all PCa patients' increasing values. The differences
between the PSAV and ANNV are also given in the Table
5. It can be seen that only BPH benefit from the additional
ANNV since the stable values are significantly more
(+17.4%). Also, there is a reduction of increasing values (-
10.6%). This avoids repeated prostate biopsies in at least
Table 1: Distribution of patients within the different PSA ranges and median values for tPSA, %fPSA and prostate volume for all 
patients
All patients PCa BPH
tPSA 
range 
(ng/mL)
number tPSA 
(ng/mL)
%fPSA 
(%)
volume 
(ml)
number tPSA 
(ng/mL)
%fPSA 
(%)
volume 
(ml)
number tPSA 
(ng/mL)
%fPSA 
(%)
volume 
(ml)
0–4 47 2.1 19.4 40 2 3.5 17.2 36.5 45 2.1 19.5 40
4.1–10 94 5.6 15.9 44.5 24 5.8 14.3* 33.5* 70 5.6 17.4 50
10.1–20 50 13.6 11 49.1 20 13.5 9.7* 44.5* 30 13.9 13.7 59
>20 8 25.7 9 35.5 3 29.3 6.8* 35* 5 25.6 11 80
all 199 6.2 15.1 45 49 8.3* 10.9* 35* 150 5.3 16.7 47
*significantly different from BPH patients with P < 0.0001BMC Urology 2008, 8:10 http://www.biomedcentral.com/1471-2490/8/10
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11% of all BPH patients. Another observation is that more
than half of all patients (52%) show an atypical PSAV
with regard to their diagnosis.
When using the traditional PSAV cutoff of 0.75 ng/mL/
year the regular median PSAV for the PCa patients was
1.24 ng/mL/year whereas the PSAV for the BPH patients
was 0.16 ng/mL/year (P  < 0.0001). Further descriptive
data are given for the patients with increasing, stable and
decreasing PSAV (Table 6) and ANNV (Table 7).
When analyzing the short-term-PSAV over 12 months, the
median PSAV for the PCa patients is higher with 1.61 ng/
mL/year but the median PSAV for the BPH patients is
almost zero with 0.04 ng/mL/year (P = 0.0001). There are
only slight differences between PCa patients when look-
ing at the PSAV for a 12 months period (data not shown).
However, around one third of all BPH patients change the
status of stable values which were visible over a long time
observation to increasing or decreasing values when only
calculating the PSAV over 12 months. Instead of 65% by
using the regular PSAV, only 32% of all BPH patients had
stable values when using the short-term-PSAV.
Discussion
The discussion regarding the use of PSAV to improve the
low specificity of PSA has gained increasing attention. Ini-
tially, Carter et al. [6] presented at a PSAV cut off of 0.75
ng/mL/year a specificity of 90% – significantly higher
than the 60% specificity of a single PSA cutoff of 4 ng/mL.
The results, though, were based on analyzing only 18 can-
cer cases [6]. In a current analysis on a large cohort of
patients the authors found that the PSAV cutoff of 0.75
ng/mL/year underestimated the risk of PCa especially in
younger men and recommended age-adjusted cutoffs [9].
However, this analysis excluded 45% of men (5,381 from
11,861 men) with a PSAV of 0 or less and 30% (504 from
1654) PCa patients without increasing PSAV. The remain-
ing 70% PCa patients had an increasing PSAV, which is
the same percentage of PCa patients as we found in our
Table 2: PSA follow up for all patients for all patient groups
all patients PCa BPH
Follow up (years) number percentage in % number percentage in % number percentage in %
0.5 to 1 12 6 6 12 6 4
1  t o  2 4 72 42 14 32 61 8
2  t o  4 5 62 81 53 14 12 7
4 to 6 41 20.5 5 10 36 24
6 to 9 43 21.5 2 4 41 27
all 199 100 49 100 150 100
Table 3: Areas under the curves (AUC), specificities at 95% sensitivity and sensitivities at 95% specificity with the respective confidence 
intervals (in parenthesis) for the parameters tPSA, %fPSA, PSAD§, PSAV, ANN and ANNV$ for all patients (n = 199)
Parameter AUC
(Confidence 
Intervals)
P-values and 
significance levels§
Specificity at 95% 
Sensitivity
P-values and 
significance levels§
Sensitivity at 95% 
Specificity
P-values and 
significance levels$
PSA 0.69
(0.61–0.77)
0.0001** 27.3
(21.4–34)
<0.0001*** 14.3
(7–25.4)
0.008**
%fPSA 0.70
(0.71–0.78)
0.007** 17.3
(12.5–23.3)
<0.0001*** 20.4
(11.6–32.3)
0.44
PSAD 0.76
(0.69–0.83)
-4 4
(37.1–51.7)
-1 6 . 3
(8.5–27.7)
0.013*
PSAV 0.76
(0.67–0.84)
0.835 4.7
(2.2–8.7)
<0.0001*** 16.3
(8.5–27.7)
0.023*
ANN 0.66
(0.57–0.75)
0.001** 10
(6.3–15.1)
<0.0001*** 18.4
(10–30)
0.023*
ANNV 0.56
(0.44–0.68)
<0.0001*** 1.3
(0.2–4.3)
<0.0001*** 32.7
(21.7–45.4)
-
§PSAD with largest AUC and highest specificity at 95% sensitivity, all others compared to PSAD
$ANNV with highest sensitivity at 95% specificity, all others compared to ANNV
*P < 0.05
**P < 0.01
***P < 0.0001BMC Urology 2008, 8:10 http://www.biomedcentral.com/1471-2490/8/10
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study with increasing PSA values (Table 5). However, in
our analysis, all patients regardless of the PSAV were con-
sidered. On the other hand, 30% of all PCa patients do
not present with the typical increasing PSA values. 10% of
all PCa patients even have decreasing PSA values. This
shows that PSAV can detect approximately 2/3 of all PCa
patients but stable or decreasing PSA values do not really
reduce the risk of having PCa if the PSA alone is elevated.
It was assumed that additional clinical and laboratory
data would improve the PCa detection rate when using
ANN models where %fPSA, age, prostate volume and the
DRE status are considered. However, this study could not
demonstrate a positive effect by using the ANNV to detect
more cancer patients since only 45% of all PCa patient
had an increasing ANNV. This is a reduction of 26.5%
compared with the PSAV. The number of stable or
decreasing ANNV output values increased compared with
the PSAV indicating that PSAV alone is the better indicator
for a PCa risk. More than half of all PCa patients had a sta-
ble or even decreasing ANNV. It should be noted that this
poor performance of the ANN is only related to the follow
up but not to the ANN use at all for PCa detection. Here it
has been demonstrated that ANN models with clinical
and laboratory values can significantly improve the PCa
detection rate compared with PSA and %fPSA [20,22-25].
However, the relatively small number of patients with
only one third PCa is a limitation of this study compared
with other ANN studies where no follow up was analyzed.
Importantly, the inclusion of the ANNV can substantially
save repeated biopsies in BPH patients. Whereas the PSAV
shows only for 65.3% of the BPH patients the typical con-
tinuous follow up, this number increases to 82.7% when
using the ANNV. Thus, at the best case approximately
17% of all BPH patients may benefit if taking into account
not only the PSA but also the ANN follow up. When only
Table 4: Areas under the curves (AUC), specificities at 95% sensitivity and sensitivities at 95% specificity with the respective confidence 
intervals (in parenthesis) for the parameters tPSA, %fPSA, PSAD§, PSAV, ANN and ANNV$ for the tPSA range 4–10 ng/mL (n = 94)
Parameter AUC
(Confidence 
Intervals)
P-values and 
significance levels§
Specificity at 95% 
Sensitivity
P-values and 
significance levels§
Sensitivity at 95% 
Specificity
P-values and 
significance levels$
PSA 0.50
(0.36–0.63)
<0.0001*** 11.4
(5.9–19.8)
0.002** 4.2
(1.3–19.1)
0.037*
%fPSA 0.64
(0.51–0.77)
0.09 20
(12.6–29.6)
0.045* 12.5
(3.5–29.7)
0.023*
PSAD 0.69
(0.58–0.81)
-3 5 . 7
(26.2–46.2)
-4 . 2
(1.3–19.1)
0.013*
PSAV 0.66
(0.53–0.80)
0.529 4.3
(1.2–11.0)
<0.0001*** 12.5
(3.5–29.7)
0.023*
ANN 0.66
(0.53–0.79)
0.264 8.6
(3.8–16.4)
<0.0001*** 16.7
(5.9–34.6)
0.074
ANNV 0.57
(0.40–0.75)
0.008** 0 <0.0001*** 37.5
(21.2–56.4)
-
§PSAD with largest AUC and highest specificity at 95% sensitivity, all others compared to PSAD
$ANNV with highest sensitivity at 95% specificity, all others compared to ANNV
*P < 0.05
**P < 0.01
***P < 0.0001
ROC curves for tPSA (green, AUC 0.5), %fPSA (blue, AUC  0.64), PSAD (black, AUC 0.69) and ANNV (red, AUC 0.57)  to show the different behavior of the curve regardless of the  AUC at tPSA 4–10 ng/mL (PSAV and ANN not shown, given  in table 4) Figure 1
ROC curves for tPSA (green, AUC 0.5), %fPSA (blue, AUC 
0.64), PSAD (black, AUC 0.69) and ANNV (red, AUC 0.57) 
to show the different behavior of the curve regardless of the 
AUC at tPSA 4–10 ng/mL (PSAV and ANN not shown, given 
in table 4).
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looking at the difference between an increasing PSAV and
increasing ANNV, the ANNV could save approximately
11% of all biopsies compared with the PSAV. As seen in
Figure 1, the ANNV has the highest sensitivities at 95%
and 90% specificity, respectively. Thus, relatively good
sensitivity values at high specificity cutoffs argue for a usa-
bility of the ANNV especially for repeat biopsies, where
biopsies in general should be avoided. This is an impor-
tant result of the study. A further possibility is to look at
partial ROC areas, which has been published before [26].
When only including the AUC between 80% and 100%
specificity, the ANNV has clearly the largest AUC com-
pared with all others. Hence, for a ROC comparison one
should not only consider the AUC but also the ROC curve
shape for a better interpretation.
Another problem is the relatively poor performance of the
PSAV alone, which can be partially explained by the bio-
logical variation of PSA of up to 20% [14]. Differences in
PSA values regarding the used assays may be also respon-
sible [15]. However, this could be excluded in our study
since only the IMMULITE assays were used for the tPSA
and fPSA measurements over the whole time period from
1996 until 2006. The use of %fPSA revealed large differ-
ences between commonly used assays [16-18]. In a recent
study on 4,480 men in 5 different populations with 5 dif-
ferent PSA and fPSA assays and the application of different
assay-adapted ANNs it has been demonstrated that our
recently multicentric evaluated ANN "ProstataClass" [22]
should not be used without consideration of the PSA
assay [25]. In another study, Okamura and colleagues
[27] reported an acceptable comparability between two
PSA assays by using a %fPSA-based logistic regression
model.
To calculate the PSAV we subdivided the PSA follow ups
into three categories with increasing (> 0.75 ng/mL/year),
stable (-0.75 to 0.75 ng/mL/year) and decreasing (< -0.75
ng/mL/year) values. The same procedure was performed
with the ANNV, where 4/year was taken as cutoff. Con-
trary to others [28], we found it difficult to further subdi-
vide also the category of inconsistent values. We did not
find it useful to determine a definitive cutoff for the ANNV
as Carter et al. [6] did for the PSAV but the cutoff 4/year
for the ANNV was taken for this preliminary study which
equals to 90% specificity to have the possibility to dis-
criminate between increasing, stable and decreasing val-
ues. However, the number of patients is relatively small
and the usefulness of a cutoff especially for the PCa detec-
tion has not been shown.
Recently, a study has reported that different methods to
calculate the PSAV either with simple arithmetic or linear
regression does not change the outcome [29]. Data from
Table 5: Comparison of the PSA and ANN velocity in PCa and BPH patients
PSA velocity (PSAV) ANN velocity (ANNV)
follow up group PCa in %
(n = 49)
BPH in %
(n = 150)
PCa in %
(n = 49)
Difference to PSAV BPH in %
(n = 150)
Difference to PSAV
increasing 71.4% 21.3% 44.9% - 26.5% 10.7% - 10.6%
stable* 18.4% 65.3% 34.7% + 16.3% 82.7% + 17.4%
decreasing 10.2% 13.3% 20.4% + 10.2% 6.7% - 6.6%
*by using the cutoff of 0.75 ng/mL/year for tPSA (range -0.75 to 0.75) and by using the cutoff of 4 per year for ANN output (range -4 to 4)
Table 6: Median values and p-values between the 3 groups of increasing, stable or decreasing PSAV values
Increasing PSAV
(>0.75 ng/mL/year)
Stable PSAV
(-0.75 to 0.75 ng/mL/year)
Decreasing PSAV
(< -0.75 ng/mL/year)
Parameter PCa (n = 35) BPH (n = 32) p-value PCa (n = 9) BPH (n = 98) p-value PCa (n = 5) BPH (n = 20) p-value
Age (years) 65 68 0.15 68 68 0.86 72 68.5 0.92
tPSA (ng/mL) 11.7* 11.5*$ 0.72 4.8§ 4.96 0.96 6.2* 4.39 0.067
%fPSA (%) 9.6*§ 14.1 0.001 15 17.4 0.49 21 16 0.13
Volume (mL) 35 46.5 0.066 33 45 0.1 55 57.5 0.89
The p-value is given for the comparison between the respective PCa and BPH patients (Mann-Whitney U Test)
*significantly different to the respective patients in the stable group (P < 0.05; Mann-Whitney U Test)
§significantly different to the respective patients in the decreasing group (P < 0.05; Mann-Whitney U Test)
The Kruskal-Wallis Test for the PCa patients between all 3 groups showed for tPSA (p = 0.0003) and %fPSA (p = 0.0008) significant differences but 
not for age (p = 0.26) or volume (p = 0.17).
The Kruskal-Wallis Test for the BPH patients between all 3 groups showed for tPSA (p < 0.0001) significant differences but not for %fPSA (p = 0.4), 
age (p = 0.96) or volume (p = 0.44).BMC Urology 2008, 8:10 http://www.biomedcentral.com/1471-2490/8/10
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this study were also not different when using the linear
regression calculated compared with the arithmetic
method (not shown).
Whereas the advantage of ANN models compared with
PSA or %fPSA has been proven in many studies [20,22],
the situation for PSAV compared with PSA is unclear
[8,11-13,30,31]. Studies on large populations have shown
a clear advantage for PSAV compared with PSA alone
[8,11,31]. Apart from PSAV, the age and the tPSA range
should be also considered [8,31]. Another study in
screened men proved a significant difference for the PSAV
between PCa (median: 0.62) and men with a negative
biopsy (median: 0.46) but could not confirm a clinical
advantage [30]. Furthermore, the studies by Thompson et
al. [13] and Schroeder et al. [12] also on large popula-
tions, did not show any advantage of using PSAV instead
o f  P S A .  I n  a  r e c e n t  r e v i e w  o n  s t u d i e s  o f  P S A V  i t  w a s
explained why the association between PSAV and disease-
specific survival, which has been shown in other studies,
does not necessarily imply that PSAV will be a useful
screening tool [32]. Moreover, other results show that
patients who have a PSA which returns to normal levels
still have a significant risk of PCa which led the authors to
the conclusion that prostate biopsy might be most appro-
priate even after a single abnormal PSA [28]. Here we only
partially agree because a simple repeated measurement of
the PSA can avoid a significant number of biopsies and
inclusion of ANN models give further certainty for a cor-
rect biopsy indication [33].
Conclusion
To conclude, this study demonstrates limited usefulness
of PSAV to detect PCa with only 71% of increasing PSA
values while approximately 30% of all PCa do not have
the typical PSA follow up. The ANNV cannot improve the
PCa detection rate but may save 11–17% of unnecessary
prostate biopsies in BPH patients. Further studies on
screening and larger populations are needed to determine
the usefulness of the ANNV.
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